Ligand Pharmaceuticals (LGND) Common Equity (2010 - 2026)

Ligand Pharmaceuticals has disclosed Common Equity across 17 years of filings, most recently posting $997.3 million for Q1 2026.

• Common Equity for Q1 2026 came in at $997.3 million, up 25.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $997.3 million (up 25.36% YoY), and the FY2025 annual result was $1.0 billion, up 22.49% from the prior year.
• Common Equity came in at $997.3 million for Q1 2026 at Ligand Pharmaceuticals, down from $1.0 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.0 billion in Q4 2025 to a low of $597.5 million in Q4 2022.
• The 5-year median for Common Equity is $802.4 million (2022), against an average of $795.9 million.
• Across the five-year window, Common Equity fell 27.24% in 2022 and increased 25.94% in 2024, its largest moves.
• Ligand Pharmaceuticals' Common Equity stood at $597.5 million in 2022, then climbed by 17.31% to $700.9 million in 2023, then increased by 18.48% to $830.4 million in 2024, then rose by 22.49% to $1.0 billion in 2025, then decreased by 1.96% to $997.3 million in 2026.
• The last three Common Equity figures came in at $997.3 million (Q1 2026), $1.0 billion (Q4 2025), and $950.2 million (Q3 2025), per Business Quant data.